Canopy Growth (CGC) Total Current Liabilities (2017 - 2026)
Canopy Growth (CGC) posted Total Current Liabilities of $115.5 million for Q1 2026, up 47.37% sequentially from $78.4 million in Q4 2025, and up 60.88% YoY from $71.8 million in Q1 2025.
Canopy Growth (CGC) Total Current Liabilities (2017 - 2026) Analysis & Trends
Canopy Growth has reported Total Current Liabilities for 10 years, with the latest figure at $115.5 million in Q1 2026.
- Quarterly Total Current Liabilities rose 60.88% year-over-year to $115.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $115.5 million (up 60.88% YoY) and the FY2026 annual result came in at $115.5 million, up 60.88% from the prior year.
- Total Current Liabilities rose to $115.5 million in Q1 2026 per CGC's latest filing, from $78.4 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $594.6 million in Q1 2023 and troughed at $70.1 million in Q3 2025.
- A 5-year average of $226.1 million and a median of $169.6 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities soared 253.28% in 2023, then slumped 71.08% in 2025.
- Over 5 years, Total Current Liabilities stood at $500.3 million in 2022, then tumbled by 66.11% to $169.6 million in 2023, then tumbled by 44.92% to $93.4 million in 2024, then declined by 16.07% to $78.4 million in 2025, then surged by 47.37% to $115.5 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $115.5 million, $78.4 million, and $70.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 1.79 Bn |
| 10 | Canopy Growth | 441.27 Mn | 194.25 Mn | 16.08 Mn | 120.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 120.55 Mn |
| Mar 31, 2026 | 115.54 Mn |
| Dec 31, 2025 | 78.40 Mn |
| Sep 30, 2025 | 70.07 Mn |
| Jun 30, 2025 | 79.86 Mn |
| Mar 31, 2025 | 71.82 Mn |
| Dec 31, 2024 | 93.41 Mn |
| Sep 30, 2024 | 239.44 Mn |
| Jun 30, 2024 | 169.92 Mn |
| Mar 31, 2024 | 248.35 Mn |
| Dec 31, 2023 | 169.58 Mn |
| Sep 30, 2023 | 161.80 Mn |
| Jun 30, 2023 | 335.86 Mn |
| Mar 31, 2023 | 594.60 Mn |
| Dec 31, 2022 | 500.33 Mn |
| Sep 30, 2022 | 428.33 Mn |
| Jun 30, 2022 | 317.33 Mn |
| Mar 31, 2022 | 168.31 Mn |
| Dec 31, 2021 | 189.80 Mn |
| Sep 30, 2021 | 206.47 Mn |